黛力新对糖尿病视网膜病变伴抑郁患者的疗效观察

目的:观察黛力新配合常规治疗对糖尿病视网膜病变(DR)伴抑郁患者抑郁评分(HAMD)、血清内脏脂肪素(Visfatin)、空腹血糖(FBG)、甘油三酯(TG)、平均血糖波动幅度(MAGE)的影响。方法:选取DR伴抑郁患者36例,随机分为对照组及黛力新组(n均=18)。对照组采用DR常规治疗,黛力新组在DR常规治疗基础上加用黛力新片,于每天早晨和中午各口服1片(0.5mg/片)。疗程均为4周。观察两组患者治疗前后临床表现,并进行HAMD评分,ELISA检测血清Visfatin,电化学法测定全血FBG,酶法测定血清TG,MiniMed动态血糖监测系统测定MAGE,并行统计学比较分析。结果:治疗前,两组患者存在明显抑郁现象,各检查指标无明显差异(P>0.05);治疗后,黛力新组临床表现改善明显,HAMD评分、Visfatin、TG、FBG、MAGE水平均下降,与对照组比较,差异有统计学意义(P<0.05)。结论:黛力新不仅能降低FBG、TG,减少MAGE,还能降低血清Visfatin水平,改善DR伴抑郁患者的抑郁状态。

Effects of Deanxits in Patient of Type 2 Diabetic Retinopathy with Depression

Objective: To investigate effects of deanxit combined with common therapy on HAMD, serum visfatin, fasting blood glucose (FBG), triglyceride(TG) and MAGE in patients of type 2 diabetic retinopathy with depression. Method: Thirtysix type 2 diabetic retinopathy (DR) patients with depression were randomly divided into two groups, the control group and the treatment group with deanxit,each group had 18 patients.Two groups had the normol therapy of DR. The treatment group took deanxit one piece orally, every morning and noon. The course of treatment was 4 weeks. Before and after treatment, the clinical manifestations were observed, the score of HAMD was estimated, serum visfatin were detected by ELISA, FBG was detected by glucose oxidase electrode,TG was assessed by enzymic method, while MAGE were measured by the Medtronic MiniMed CGMS and analyzed statistically. Results: The two groups had signs of depression obviously, and each detecting index in the two groups had no significant difference before treatment. After 4 weeks' treatment, signs of depression in deanxit group were better. and compared with the control group, HAMD, serum Visfatin, TG, FBG and MAGE were obviously decreased, the differences were statistically significant(P<0.05). Conclusion: Deanxit decreased FBG,TG,MAGE and serum visfatin, and improved the depressin of type 2 diabetic retinopathy.